Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 9;11(4):915.
doi: 10.3390/jcm11040915.

Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation

Mario Piergiulio Pezzo  1 , Antonella Tufano  2 , Massimo Franchini  1
Affiliations
Review

Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation

Mario Piergiulio Pezzo et al. J Clin Med. .

Abstract

Ischemic stroke risk in atrial fibrillation differs from patient to patient, depending on numerous variables. Many attempts have been made to translate this difference into simple numbers and to compare it to the hemorrhagic risk of anticoagulation. Different clinical scores have been studied to define a clear strategy. One score, the CHA2DS2-VASc score, has been extensively and successfully applied worldwide. Nevertheless, it is not yet the "perfect instrument". Many proposals have been made to integrate its clinical parameters with some biomarkers to improve its predictive power. This short review describes some of these biomarkers and their possible implications in potentiating the efficacy of clinical scores.

Keywords: atrial fibrillation; biomarkers; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro heart survey on atrial fibrillation. Chest. 2010;137:263–272. doi: 10.1378/chest.09-1584. - DOI - PubMed
    1. Olesen J.B., Lip G.Y., Hansen M.L., Hansen P.R., Tolstrup J.S., Lindhardsen J., Selmer C., Ahlehoff O., Olsen A.M., Gislason G.H., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124. - DOI - PMC - PubMed
    1. Kim T.H., Yang P.S., Yu H.T., Jang E., Uhm J.S., Kim J.Y., Pak H.-N., Lee M.-H., Joung B., Lip G.Y. Age threshold for ischemic stroke risk in atrial fibrillation. Stroke. 2018;49:1872–1879. doi: 10.1161/STROKEAHA.118.021047. - DOI - PubMed
    1. Li W., Zeng X., Xu L., Wang T., Lin W., Li Y., Luo Y., Luo B. Optimized stratification of risk factors in and beyond the CHA 2 DS 2 -VASc score to differentiate the real thromboembolic risk in mainland China: A systematic review and meta-analysis. Ann. Palliat. Med. 2020;9:4252–4261. doi: 10.21037/apm-20-297. - DOI - PubMed
    1. Golwala H., Jackson L.R., 2nd, Simon D.N., Piccini J.P., Gersh B., Go A.S., Hylek E.M., Kowey P.R., Mahaffey K.W., Thomas L., et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from outcomes registry for better informed treatment for atrial fibrillation registry. Am. Heart J. 2016;174:29–36. doi: 10.1016/j.ahj.2015.10.028. - DOI - PubMed

LinkOut - more resources